医药生物行业：2025年报业绩增长超预期，三大板块协同发力，核心盈利韧性凸显

Investment Rating - The investment rating for the company is "Accumulate (Maintain)" with a current price of 23.65 yuan [1] Core Views - The company reported a significant increase in revenue and net profit for the year 2025, with revenue reaching 406 million yuan, a year-on-year growth of 19.62%, and net profit of 62.73 million yuan, up 46.39% year-on-year, indicating better-than-expected performance [4][7] - The company's three main business segments are driving revenue growth, with the vaccine culture medium business recovering post-pandemic, the food nutrition segment contributing stable growth, and the raw material drug business benefiting from inventory digestion in the distribution sector [7] - The report maintains an "Accumulate" rating, with adjusted profit forecasts for 2025-2027, expecting revenues of 405.49 million yuan, 480.26 million yuan, and 564.06 million yuan, respectively, and net profits of 62.73 million yuan, 69.42 million yuan, and 88.16 million yuan, respectively [7] Financial Performance Summary - For 2025, the company achieved total revenue of 406 million yuan, a 19.62% increase, and a net profit of 62.73 million yuan, reflecting a 46.39% increase year-on-year [4][7] - The company's basic earnings per share (EPS) for 2025 is projected at 0.81 yuan, a 47.27% increase compared to the previous year [7] - The total assets at the end of 2025 reached 890 million yuan, a 10.63% increase from the beginning of the year, while the net assets attributable to shareholders were 710 million yuan, with a net asset per share of 9.14 yuan, up 7.53% [7] Financial Forecasts - Revenue forecasts for 2023A, 2024A, 2025E, 2026E, and 2027E are 389.06 million yuan, 338.98 million yuan, 405.49 million yuan, 480.26 million yuan, and 564.06 million yuan, respectively [6] - Net profit forecasts for the same years are 53.41 million yuan, 42.85 million yuan, 62.73 million yuan, 69.42 million yuan, and 88.16 million yuan, respectively [6] - The projected P/E ratios for 2025-2027 are 29.29, 26.47, and 20.84 times, respectively [7]